RT Book, Section
A1 Stolker, Joshua M.
A1 Kim, Dae H.
A1 Rich, Michael W.
A2 Fuster, Valentin
A2 Harrington, Robert A.
A2 Narula, Jagat
A2 Eapen, Zubin J.
SR Print(0)
ID 1161715781
T1 CARDIOVASCULAR DISEASE IN THE ELDERLY: PATHOPHYSIOLOGY AND CLINICAL IMPLICATIONS
T2 Hurst's The Heart, 14e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071843249
LK accesscardiology.mhmedical.com/content.aspx?aid=1161715781
RD 2024/04/18
AB Most  cardiovascular  diseases  (CVDs)  increase  in  prevalence  and  severity  with  age,  and  most  clinicians  provide  care  for  a  substantial  number  of  elderly  patients  with  disorders  of  the  heart  and  vascular  system.  According  to  the  American  Heart  Association,  nearly  70%  of  all  US  adults  ≥  60  years  old  and  more  than  85%  of  those  ≥  80  years  old  have  known  CVD  (Fig.  65–1).1  Despite  earlier  treatment  of  risk  factors  and  progressive  improvements  in  therapies  over  the  past  several  decades,  heart  disease  remains  the  leading  cause  of  death  in  the  Medicare  population.  Furthermore,  more  than  half  of  all  cardiovascular  procedures  in  the  United  States  are  performed  in  patients  aged  65  years  and  older,  and  the  total  cost  for  CVD  in  this  population  exceeded  $115  billion  in  2011.1  With  the  progressive  aging  of  our  population,2,3  these  figures  will  continue  to  rise.  For  these  reasons,  an  understanding  of  the  effects  of  aging  on  the  development  of  CVD  and  the  utility  of  cardiovascular  therapies  in  the  context  of  other  age-related  medical  concerns  (eg,  multimorbidity,  polypharmacy,  frailty)  is  critical  for  reducing  risk  and  improving  outcomes  in  older  patients.